Literature DB >> 23321469

Proteomic analysis of interleukin enhancer binding factor 3 (Ilf3) and nuclear factor 90 (NF90) interactome.

Alexandre Chaumet1, Sandrine Castella, Laïla Gasmi, Aurélie Fradin, Gilles Clodic, Gérard Bolbach, Robert Poulhe, Philippe Denoulet, Jean-Christophe Larcher.   

Abstract

Interleukin enhancer binding factor 3 (Ilf3) and Nuclear Factor 90 (NF90) are two ubiquitous proteins generated by alternative splicing from the ILF3 gene that provides each protein with a long and identical N-terminal domain of 701 amino acids and a specific C-terminal domain of 210 and 15 amino acids, respectively. They exhibit a high polymorphism due to their posttranscriptional and posttranslational modifications. Ilf3 and NF90 functions remain unclear although they have been described as RNA binding proteins but have been implicated in a large scale of cellular phenomena depending on the nature of their interacting partners, the composition of their protein complexes and their subcellular localization. In order to better understand the functions of Ilf3 and NF90, we have investigated their protein partners by an affinity chromatography approach. In this report, we have identified six partners of Ilf3 and NF90 that interact with their double-stranded RNA binding motifs: hnRNP A/B, hnRNP A2/B1, hnRNP A3, hnRNP D, hnRNP Q and PSF. These hnRNP are known to be implicated in mRNA stabilization, transport and/or translation regulation whereas PSF is a splicing factor. Furthermore, Ilf3, NF90 and most of their identified partners have been shown to be present in large complexes. Altogether, these data suggest an implication of Ilf3 and NF90 in mRNA metabolism. This work allows to establish a link between Ilf3 and NF90 functions, as RNA binding proteins, and their interacting partners implicated in these functions.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23321469     DOI: 10.1016/j.biochi.2013.01.004

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  7 in total

1.  NF90-NF45 is a selective RNA chaperone that rearranges viral and cellular riboswitches: biochemical analysis of a virus host factor activity.

Authors:  Tobias Schmidt; Susann Friedrich; Ralph Peter Golbik; Sven-Erik Behrens
Journal:  Nucleic Acids Res       Date:  2017-12-01       Impact factor: 16.971

2.  Expression of leukemia inhibitory factor in Müller glia cells is regulated by a redox-dependent mRNA stability mechanism.

Authors:  Cavit Agca; Karsten Boldt; Andrea Gubler; Isabelle Meneau; Armelle Corpet; Marijana Samardzija; Manuel Stucki; Marius Ueffing; Christian Grimm
Journal:  BMC Biol       Date:  2015-04-25       Impact factor: 7.431

3.  NF45 and NF90 Bind HIV-1 RNA and Modulate HIV Gene Expression.

Authors:  Yan Li; Michael Belshan
Journal:  Viruses       Date:  2016-02-16       Impact factor: 5.048

4.  Interleukin enhancer-binding factor 3 and HOXC8 co-activate cadherin 11 transcription to promote breast cancer cells proliferation and migration.

Authors:  Yang Zhang; Chenchen Yang; Mingsheng Zhang; Houli Liu; Chen Gong; Jie Zhang; Shanshan Xu; Jin Zou; Yuanzhong Kai; Yong Li
Journal:  Oncotarget       Date:  2017-11-18

5.  NF90/ILF3 is a transcription factor that promotes proliferation over differentiation by hierarchical regulation in K562 erythroleukemia cells.

Authors:  Ting-Hsuan Wu; Lingfang Shi; Jessika Adrian; Minyi Shi; Ramesh V Nair; Michael P Snyder; Peter N Kao
Journal:  PLoS One       Date:  2018-03-28       Impact factor: 3.240

6.  ILF3 Is a Negative Transcriptional Regulator of Innate Immune Responses and Myeloid Dendritic Cell Maturation.

Authors:  Rodolfo Nazitto; Lynn M Amon; Fred D Mast; John D Aitchison; Alan Aderem; Jarrod S Johnson; Alan H Diercks
Journal:  J Immunol       Date:  2021-05-24       Impact factor: 5.426

7.  High expression of interleukin-enhancer binding factor 3 predicts poor prognosis in patients with lung adenocarcinoma.

Authors:  Zhangyan Xu; Hua Huang; Xing Li; Cheng Ji; Yifei Liu; Xiaojuan Liu; Jun Zhu; Zhendong Wang; Haijian Zhang; Jiahai Shi
Journal:  Oncol Lett       Date:  2020-01-22       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.